Pasithea Therapeutics (KTTA) announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology, ASCO, taking place May 30 – June 3, 2025, in Chicago, Illinois. The Company will present updated interim clinical data from its ongoing Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA: